Hjem › Tripelnegativ brystkreft › Kentucky
Kliniske studier for Tripelnegativ brystkreft i Kentucky
6 studier for Tripelnegativ brystkreft søker deltakere på steder i Kentucky.
Byer i Kentucky
Offisiell studietekst (engelsk)
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0044), Edgewood
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06393374Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Norton Cancer Institute, Louisville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT05983432Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Norton Healthcare, Inc., Louisville
- Mercy Health, Paducah
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT05633654Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- University of Kentucky-Lexington, Lexington
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT05846789Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Norton Cancer Institute /ID# 248903, Louisville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 23. jun. 2026 · NCT05005403The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
- Baptist Health Clinical Research, Elizabethtown
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 27. apr. 2022 · NCT05037825Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.